From the pitcher's mound to the world of medicine

There was the near triple play in the ’92 Atlanta Braves series, denied by a call. Roberto Alomar’s golden glove. The lightning speed of Devon White. Joe Carter’s walk-off home run to clinch the ’93 title.

As the team’s physician, 91�Թ� alumnus Ron Taylor saw them all — from the bench.

But those weren’t the first championship games he’d seen. Before swinging into a mid-life career in medicine, Taylor pitched in the major leagues.

“I threw hard and low to the ground, so I got a lot of ground balls and strikeouts,” says Taylor, who started with the Cleveland Indians in 1962.

Over his 16-year career, the right-hander tossed for the Houston Astros and San Diego Padres, and faced off against batters in two World Series matchups — with the St. Louis Cardinals in 1964 and the New York Mets in 1969. In four World Series relief appearances, Taylor — known for his signature sinker-slider pitch — didn’t give up a single hit.

It was around the 500-game mark that Taylor decided to swap his mitt for the stethoscope. Though he had a 91�Թ� engineering degree from 1961, Taylor wanted to explore a career in medicine. At first, the Faculty of Medicine’s associate dean thought Taylor was a little old for med school.

“He asked what I had been doing and didn’t seem to have any idea what baseball was,” jokes Taylor, now 75. But when he presented his straight As in engineering, the administrator guided him into the necessary pre-med courses.

Taylor focused on sports medicine during his internship, becoming an MD in 1977. Several years later it was only natural for the Blue Jays to hire him as team doctor.

After 35 years with the team, the father of two retired from the Jays organization last year, but remains a consultant.

He still runs a family practice in Toronto and works at Mount Sinai Hospital’s S.C. Cooper Sports Medicine Clinic, which he helped found in 1980.

“There’s no substitute for passion, whatever you do," says Taylor. "I was focused as a ball player, I was focused as an engineer, and I became focused as a doctor.”

Check out this story and more in the Spring 2013 issue of 91�Թ� Medicine Magazine.

picpath

sites/default/files/BaseballCard-13-04-30.jpg

Improving lung transplant surgery around the world

sgupta — Tue, 02 Oct 2012 10:04:12 +0000

Improving lung transplant surgery around the world sgupta Tue, 10/02/2012 - 06:04

Cutline

From 91�Թ� med student to surgeon-in-chief

Angela Pirisi

Author legacy

Angela Pirisi

Topic

Professor Shaf Keshavjee still remembers the day in 1983 when he heard exciting news on his car radio: 91�Թ� surgeons had performed the world’s first successful lung transplant at Toronto General Hospital.

“I thought, that’s cool—I would never have thought you could transplant lungs,” recalls Keshavjee, a 91�Թ� medical student at the time.

Three years later, another world first occurred—a double-lung transplant—and Keshavjee was there, as a junior 91�Թ� MD resident assigned to thoracic surgery at Toronto General Hospital.

“History was being made and I was a part of it,” he says.

Keshavjee has been part of many other firsts since then.

Keshavjee, who received his MD in 1985 and his MSc in 1990 is now a professor in 91�Թ�’s Department of Surgery, Director of the Toronto Lung Transplant Program and Surgeon-in-Chief at University Health Network (UHN). He has performed more than 300 transplants to date, most of them double-lung, and is a driving force behind innovations that have transformed lung transplantation globally.

His development of a lung preservation solution—which boosted the patient survival rate for single-lung transplants from 50 per cent to over 90 per cent—is now a world standard.

Keshavjee says 91�Թ�’s Surgical Scientist Program facilitates such innovation.

“One of the great things about the University is that surgeons can take time out of their clinical work for science. After spending two years conducting research from 1987 to 1989, I was able to develop the preservation solution in the lab and translate it into clinical practice,” he says.

Keshavjee is glad he chose 91�Թ�, despite receiving two open scholarships from elsewhere.

“91�Թ� gives one the confidence and ability to play on the international stage, to do things that are truly shoulder to shoulder with the world’s best institutions.”

Since his time as a trainee at 91�Թ�, Keshavjee has also developed a type of gene therapy to make donor lungs less prone to rejection by the immune system, and figured out a way to improve gene therapy too. The result is an ex-vivo technique—basically a breathing lung in a box—that allows an organ to remain outside the body and recover at normal body temperature.

Currently, 85 per cent of donor lungs are not used because it’s uncertain whether the human lung will work, says Keshavjee, who is also the Director of Latner Thoracic Research Laboratories and holds the James Wallace McCutcheon Chair in Surgery at UHN. But with the ex-vivo technique, clinicians can confirm that a lung will work and, if there’s a problem, use targeted gene and cell therapies to repair it, he says.

Keshavjee has performed 53 lung transplants using the method, which is now being adopted by surgeons around the world. The hope is that this approach will triple or quadruple the number of viable transplants.

“There are many people living full, productive lives because of what we do,” says Keshavjee. “But what’s also gratifying is taking transplant surgery to the next level and asking, ‘how can we do this better?’”

picpath

sites/default/files/Keshavjee_12_09_27.jpg